vs

Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and HomeTrust Bancshares, Inc. (HTB). Click either name above to swap in a different company.

BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $53.6M, roughly 1.6× HomeTrust Bancshares, Inc.). On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 3.7%). HomeTrust Bancshares, Inc. produced more free cash flow last quarter ($45.3M vs $6.5M).

BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.

HomeTrust Bancshares Inc. is an Asheville, North Carolina–based bank holding company with $4.3 billion in assets and 33 branches in North and South Carolina, Georgia and Tennessee. It is the parent of seven community banks—HomeTrust Bank, Tryon Federal Bank, Shelby Savings Bank, Home Savings Bank, Industrial Federal Bank, Cherryville Federal Bank and Rutherford County Bank.

BLLN vs HTB — Head-to-Head

Bigger by revenue
BLLN
BLLN
1.6× larger
BLLN
$83.5M
$53.6M
HTB
Growing faster (revenue YoY)
BLLN
BLLN
+113.7% gap
BLLN
117.4%
3.7%
HTB
More free cash flow
HTB
HTB
$38.9M more FCF
HTB
$45.3M
$6.5M
BLLN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
BLLN
BLLN
HTB
HTB
Revenue
$83.5M
$53.6M
Net Profit
$5.7M
Gross Margin
69.9%
Operating Margin
11.5%
37.0%
Net Margin
6.8%
Revenue YoY
117.4%
3.7%
Net Profit YoY
138.3%
EPS (diluted)
$0.10
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLLN
BLLN
HTB
HTB
Q4 25
$53.6M
Q3 25
$83.5M
$54.1M
Q2 25
$54.4M
Q1 25
$50.9M
Q4 24
$51.7M
Q3 24
$38.4M
$50.6M
Q2 24
$50.6M
Q1 24
$50.0M
Net Profit
BLLN
BLLN
HTB
HTB
Q4 25
Q3 25
$5.7M
$16.5M
Q2 25
$17.2M
Q1 25
$14.5M
Q4 24
Q3 24
$-14.9M
$13.1M
Q2 24
$12.4M
Q1 24
$15.1M
Gross Margin
BLLN
BLLN
HTB
HTB
Q4 25
Q3 25
69.9%
Q2 25
Q1 25
Q4 24
Q3 24
52.6%
Q2 24
Q1 24
Operating Margin
BLLN
BLLN
HTB
HTB
Q4 25
37.0%
Q3 25
11.5%
38.5%
Q2 25
40.1%
Q1 25
36.2%
Q4 24
35.4%
Q3 24
-32.9%
33.2%
Q2 24
31.3%
Q1 24
38.0%
Net Margin
BLLN
BLLN
HTB
HTB
Q4 25
Q3 25
6.8%
30.5%
Q2 25
31.6%
Q1 25
28.5%
Q4 24
Q3 24
-38.8%
25.9%
Q2 24
24.6%
Q1 24
30.1%
EPS (diluted)
BLLN
BLLN
HTB
HTB
Q4 25
$0.93
Q3 25
$0.10
$0.95
Q2 25
$1.00
Q1 25
$0.84
Q4 24
$0.83
Q3 24
$-1.47
$0.76
Q2 24
$0.73
Q1 24
$0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLLN
BLLN
HTB
HTB
Cash + ST InvestmentsLiquidity on hand
$195.2M
$324.7M
Total DebtLower is stronger
$55.0M
Stockholders' EquityBook value
$-239.5M
$600.7M
Total Assets
$327.5M
$4.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLLN
BLLN
HTB
HTB
Q4 25
$324.7M
Q3 25
$195.2M
$315.8M
Q2 25
$297.2M
Q1 25
$299.8M
Q4 24
$279.2M
Q3 24
$293.5M
Q2 24
$294.2M
Q1 24
$380.5M
Total Debt
BLLN
BLLN
HTB
HTB
Q4 25
Q3 25
$55.0M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BLLN
BLLN
HTB
HTB
Q4 25
$600.7M
Q3 25
$-239.5M
$595.8M
Q2 25
$579.3M
Q1 25
$565.4M
Q4 24
$551.8M
Q3 24
$-242.9M
$540.0M
Q2 24
$523.6M
Q1 24
$513.2M
Total Assets
BLLN
BLLN
HTB
HTB
Q4 25
$4.5B
Q3 25
$327.5M
$4.6B
Q2 25
$4.6B
Q1 25
$4.6B
Q4 24
$4.6B
Q3 24
$4.6B
Q2 24
$4.7B
Q1 24
$4.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLLN
BLLN
HTB
HTB
Operating Cash FlowLast quarter
$13.8M
$49.5M
Free Cash FlowOCF − Capex
$6.5M
$45.3M
FCF MarginFCF / Revenue
7.7%
84.5%
Capex IntensityCapex / Revenue
8.8%
7.8%
Cash ConversionOCF / Net Profit
2.42×
TTM Free Cash FlowTrailing 4 quarters
$93.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLLN
BLLN
HTB
HTB
Q4 25
$49.5M
Q3 25
$13.8M
$-11.3M
Q2 25
$-8.8M
Q1 25
$71.7M
Q4 24
$45.4M
Q3 24
$43.8M
Q2 24
$5.9M
Q1 24
$-9.0M
Free Cash Flow
BLLN
BLLN
HTB
HTB
Q4 25
$45.3M
Q3 25
$6.5M
$-12.0M
Q2 25
$-10.2M
Q1 25
$70.7M
Q4 24
$42.4M
Q3 24
$43.1M
Q2 24
$5.7M
Q1 24
$-9.6M
FCF Margin
BLLN
BLLN
HTB
HTB
Q4 25
84.5%
Q3 25
7.7%
-22.2%
Q2 25
-18.7%
Q1 25
138.7%
Q4 24
82.0%
Q3 24
85.1%
Q2 24
11.2%
Q1 24
-19.2%
Capex Intensity
BLLN
BLLN
HTB
HTB
Q4 25
7.8%
Q3 25
8.8%
1.4%
Q2 25
2.5%
Q1 25
2.0%
Q4 24
5.9%
Q3 24
1.3%
Q2 24
0.5%
Q1 24
1.1%
Cash Conversion
BLLN
BLLN
HTB
HTB
Q4 25
Q3 25
2.42×
-0.68×
Q2 25
-0.51×
Q1 25
4.93×
Q4 24
Q3 24
3.34×
Q2 24
0.48×
Q1 24
-0.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLLN
BLLN

Prenatal$74.1M89%
Oncology$8.7M10%

HTB
HTB

Segment breakdown not available.

Related Comparisons